Achievement of Treat-to-Target Thresholds with Envudeucitinib, a Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Results from STRIDE and OLE. J of Skin [Internet]. 2025 Nov. 10 [cited 2026 May 2];9(6):s650. Available from: https://skin.dermsquared.com/skin/article/view/3905